Literature DB >> 17530391

Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Soo Jung Lee1, Young-Ok Son, Hyunjin Kim, Joo-Young Kim, Soon-Won Park, Jae-Ho Bae, Hyung Hoi Kim, Eun-Yup Lee, Byung-Seon Chung, Sun-Hee Kim, Chi-Dug Kang.   

Abstract

Despite long-term use of mistletoe extracts for cancer treatment, their mode of action remains elusive. In this study, it was studied in vitro if mistletoe extract is able to modulate the expression of natural cytotoxic receptors (NCRs) and NKG2D receptor, which stimulate natural killer cell-mediated cytotoxicity. Unexpectedly, a mistletoe extract, ABNOBA viscum Fraxini, inhibited the expression level of NKp46 and NKG2D receptors in dose- and time-dependent manners. The levels of NKp30 and NKG2D receptors were remarkably induced and NKp44 was slightly induced after 48 h treatment with IL-2 and IL-15 in both mRNA and surface expression. The activatory NK receptors were not induced significantly after treatment with IL-12, IL-18, and IL-21 for 48 h. Induction of activatory NK receptors by IL-2 and IL-15 was suppressed almost to the untreated levels by treatment with mistletoe extract, which appeared to induce apoptosis of NK cells in a dose-dependent manner. However, the treatment with IL-2 and IL-15 did not prevent the mistletoe-induced NK-cell death. Mistletoe extract inhibited significantly the cytotoxic activity of resting and IL-2- or IL-15-stimulated NK cells. These results suggest that inhibition of survival and function of NK cells by mistletoe extract may curtail in part the therapeutic effects of mistletoe.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530391     DOI: 10.1007/s10875-007-9098-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  41 in total

Review 1.  Surface NK receptors and their ligands on tumor cells.

Authors:  Lorenzo Moretta; Cristina Bottino; Daniela Pende; Roberta Castriconi; Maria Cristina Mingari; Alessandro Moretta
Journal:  Semin Immunol       Date:  2006-05-26       Impact factor: 11.130

Review 2.  Mistletoe for cancer? A systematic review of randomised clinical trials.

Authors:  Eduard Ernst; Katja Schmidt; Miriam Katharina Steuer-Vogt
Journal:  Int J Cancer       Date:  2003-11-01       Impact factor: 7.396

3.  Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma.

Authors:  Jean-Paul Duong Van Huyen; Sandrine Delignat; Jagadeesh Bayry; Michel D Kazatchkine; Patrick Bruneval; Antonino Nicoletti; Srini V Kaveri
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

4.  A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells.

Authors:  K Hostanska; T Hajto; G C Spagnoli; J Fischer; H Lentzen; R Herrmann
Journal:  Nat Immun       Date:  1995-09

5.  The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. The RNA N-glycosidase activity of the protein.

Authors:  Y Endo; K Tsurugi; H Franz
Journal:  FEBS Lett       Date:  1988-04-25       Impact factor: 4.124

6.  Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells.

Authors:  E A Mueller; F A Anderer
Journal:  Immunopharmacology       Date:  1990 Jan-Feb

7.  [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].

Authors:  J Beuth; B Stoffel; H L Ko; G Buss; L Tunggal; G Pulverer
Journal:  Arzneimittelforschung       Date:  1995-04

Review 8.  [Mistletoe therapy from the pharmacologic perspective].

Authors:  T Hajto; K Hostanska; R Saller
Journal:  Forsch Komplementarmed       Date:  1999-08

9.  Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract.

Authors:  G Kuttan
Journal:  Immunol Invest       Date:  1993 Aug-Oct       Impact factor: 3.657

10.  Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients.

Authors:  T Hajto; C Lanzrein
Journal:  Oncology       Date:  1986       Impact factor: 2.935

View more
  3 in total

1.  Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.

Authors:  Anja Thronicke; Megan L Steele; Christian Grah; Burkhard Matthes; Friedemann Schad
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

2.  Mistletoe-Extract Drugs Stimulate Anti-Cancer Vγ9Vδ2 T Cells.

Authors:  Ling Ma; Swati Phalke; Caroline Stévigny; Florence Souard; David Vermijlen
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

3.  Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.

Authors:  Friedemann Schad; Anja Thronicke; Megan L Steele; Antje Merkle; Burkhard Matthes; Christian Grah; Harald Matthes
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.